Literature DB >> 12217490

Lessons from constitutively active mutants of G protein-coupled receptors.

Charles Parnot1, Stéphanie Miserey-Lenkei, Sabine Bardin, Pierre Corvol, Eric Clauser.   

Abstract

In the past decade, the concept of constitutive activity has profoundly modified our understanding of G protein-coupled-receptors (GPCRs). Here, we review the contribution of constitutively active mutants (CAMs) to our understanding of three aspects of GPCR physiopathology: (1) GPCR activation is a complex mechanism involving both the release of inactive state conformational constraints, mimicked by most CAMs, and the creation of new interactions that stabilize the active state and are mimicked by a restricted set of CAMs; (2) GPCR phosphorylation, internalization and desensitization processes are activated by receptor conformations, which partly overlap those activating G protein; (3) natural CAMs, mostly affecting GPCRs of the endocrine system, are found in several hereditary and acquired diseases, including cancers. One major remaining question is how CAMs recapitulate the different structural modifications of the agonist-induced active conformation(s) of the wild-type receptor. This characterization is a prerequisite for further use of CAMs as ligand-free models of active GPCRs in structural, cellular and physiological studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217490     DOI: 10.1016/s1043-2760(02)00628-8

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  43 in total

1.  Subclinical nonautoimmune hyperthyroidism in a family segregates with a thyrotropin receptor mutation with weakly increased constitutive activity.

Authors:  Eijun Nishihara; Chun-Rong Chen; Takuya Higashiyama; Yumiko Mizutori-Sasai; Mitsuru Ito; Sumihisa Kubota; Nobuyuki Amino; Akira Miyauchi; Basil Rapoport
Journal:  Thyroid       Date:  2010-10-07       Impact factor: 6.568

2.  A signal transduction pathway model prototype I: From agonist to cellular endpoint.

Authors:  Thomas J Lukas
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

3.  Constitutively active G protein-coupled receptor mutants block dictyostelium development.

Authors:  Minghang Zhang; Mousumi Goswami; Dale Hereld
Journal:  Mol Biol Cell       Date:  2004-12-01       Impact factor: 4.138

4.  Comparison of class A and D G protein-coupled receptors: common features in structure and activation.

Authors:  Markus Eilers; Viktor Hornak; Steven O Smith; James B Konopka
Journal:  Biochemistry       Date:  2005-06-28       Impact factor: 3.162

Review 5.  G protein coupled receptor structure and activation.

Authors:  Brian K Kobilka
Journal:  Biochim Biophys Acta       Date:  2006-11-15

6.  Simplified modeling approach suggests structural mechanisms for constitutive activation of the C5a receptor.

Authors:  Gregory V Nikiforovich; Garland R Marshall; Thomas J Baranski
Journal:  Proteins       Date:  2010-11-30

Review 7.  Structure, function and physiological consequences of virally encoded chemokine seven transmembrane receptors.

Authors:  M M Rosenkilde; M J Smit; M Waldhoer
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

Review 8.  Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics.

Authors:  Ya-Xiong Tao
Journal:  Pharmacol Ther       Date:  2008-08-09       Impact factor: 12.310

9.  Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A.

Authors:  Li Wang; Caius G Radu; Li V Yang; Laurent A Bentolila; Mireille Riedinger; Owen N Witte
Journal:  Mol Biol Cell       Date:  2005-02-23       Impact factor: 4.138

10.  The third intracellular loop stabilizes the inactive state of the neuropeptide Y1 receptor.

Authors:  Melissa J S Chee; Karin Mörl; Diana Lindner; Nicole Merten; Gerald W Zamponi; Peter E Light; Annette G Beck-Sickinger; William F Colmers
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.